Sign up Australia
Proactive Investors - Run By Investors For Investors

Race Oncology reveals promising results for its chemotherapy drug

Two girls in France have had a successful response to the treatment with Bisantrene.
cancer cells
Granted an Orphan Drug Designation in the US

Race Oncology Ltd (ASX:RAC) has revealed a case report describing the successful use of Bisantrene to treat childhood relapsed/refractory AML (Acute Myeloid Leukaemia).

Bisantrene is a small-molecule chemotherapy drug related to anthracyclines, the most frequently prescribed type of cancer drug and first line of treatment for many cancers.

Race owns two patents on Bisantrene, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML.

Two girls in France fully respond to treatment

The case report describes two girls in France who were successfully treated with Bisantrene in 1984 and 1991. Both remain alive today.

Race chief executive officer Peter Molloy explained: “One of the girls was seven years old when diagnosed with AML in 1984”

“She had relapsed after multiple lines of standard chemotherapy and was treated with one 7-day course of Bisantrene, followed by other chemotherapy.

“She had a complete response to the treatment, which allowed her to receive a bone marrow transplant. As a result, she’s alive today and the mother of three children.”

WATCH: Race Oncology director sees "extreme, untapped value" in company's cancer drug

The other girl was 13 years old when diagnosed in 1990 and also had relapsed after multiple lines of standard chemotherapy.

In 1991, she received Bisantrene treatment in combination with two standard chemotherapy agents.

Molloy added: “She also had a complete response, which allowed her to receive a bone marrow graft. Thankfully, she is still alive today and has a three-year old child.”

View full RAC profile View Profile

Race Oncology Ltd Timeline

Newswire
February 15 2017

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use